“Therapeutic and adverse effects of standard-dose and low-dose meglumine antimoniate during systemic treatment of Syrian cutaneous leishmaniasis patients” (2016) Journal of Pakistan Association of Dermatologists, 24(2), pp. 115–121. doi:10.66344/jpad.v24i2.189.